Peter Thomson

Peter Thomson joined Fulcrum in 2018, bringing over 15 years of experience in the life sciences industry. Most recently, he was a consultant for three Third Rock Ventures portfolio companies, where he served as interim head of finance. Before that, he served as head of finance at BIND Therapeutics, where he oversaw all finance and accounting activities, developed the corporate valuation for the company and played an integral role in the company’s sale to Pfizer. Prior to BIND, he was senior director of finance at Ovascience and director of finance at Millennium: The Takeda Oncology Company. In addition, he held positions on the finance teams at Boston Scientific Corporation, Infomedics, Inc., and the Hewlett-Packard Company. Peter earned a bachelor’s from Brown University and an MBA from the University of Chicago Booth School of Business.